Subdividing Ovarian and Peritoneal Serous Carcinoma Into Moderately Differentiated and Poorly Differentiated Does not Have Biologic Validity Based on Molecular Genetic and In Vitro Drug Resistance Data-Reference-Cited by-同舟云学术

Subdividing Ovarian and Peritoneal Serous Carcinoma Into Moderately Differentiated and Poorly Differentiated Does not Have Biologic Validity Based on Molecular Genetic and In Vitro Drug Resistance Data

Published:2008-11 Issue:11 Volume:32 Page:1667-1674
ISSN:0147-5185
Container-title:American Journal of Surgical Pathology
language:en
Short-container-title:

Author:

Vang Russell,Shih Ie-Ming,Salani Ritu,Sugar Elizabeth,Ayhan Ayse,Kurman Robert J.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pathology and Forensic Medicine,Surgery,Anatomy

Reference33 articles.

1. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium;Acs;Int J Gynecol Pathol,2004

2. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?;Ayhan;Int J Gynecol Cancer,2006

3. Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study;Barda;Am J Obstet Gynecol,2004

4. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful;Barnetson;Am J Clin Pathol,2006

5. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma;Ben-Baruch;Gynecol Oncol,1996

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opening the Black Box: Spatial Transcriptomics and the Relevance of Artificial Intelligence–Detected Prognostic Regions in High-Grade Serous Carcinoma;Modern Pathology;2024-07

2. Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing;npj Precision Oncology;2023-05-18

3. New therapeutic opportunities for women with low-grade serous ovarian cancer;Endocrine-Related Cancer;2022-01-01

4. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base;Gynecologic Oncology;2019-09

5. Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer;Scientific Reports;2019-07-24